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Control and Epidemiology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, FranceAbstractBioﬁlm formation, intra-osteoblastic persistence, small-colony variants (SCVs) and the dysregulation of agr, the major virulence regulon, are
possibly involved in staphylococcal bone and joint infection (BJI) pathogenesis. We aimed to investigate the contributions of these mechanisms
among a collection of 95 Staphylococcus aureus clinical isolates from 64 acute (67.4%) and 31 chronic (32.6%) ﬁrst episodes of BJI. The included
isolates were compared for internalization rate, cell damage and SCV intracellular emergence using an ex vivo model of human osteoblast
infection. Bioﬁlm formation was assessed in a microbead immobilization assay (BioFilm Ring test). Virulence gene proﬁles were assessed
by DNA microarray. Seventeen different clonal complexes were identiﬁed among the screened collection. The staphylococcal
internalization rate in osteoblasts was signiﬁcantly higher for chronic than acute BJI isolates, regardless of the genetic background.
Conversely, no differences regarding cytotoxicity, SCV emergence, bioﬁlm formation and virulence gene distribution were observed.
Additionally, agr dysfunction, detected by the lack of delta-toxin production using whole-cell matrix-assisted laser desorption ionization
time-of-ﬂight (MALDI-TOF) analysis (n = 15; 15.8%), was signiﬁcantly associated with BJI chronicity, osteoblast invasion and bioﬁlm
formation. These ﬁndings provide new insights into MSSA BJI pathogenesis, suggesting the correlation between chronicity and
staphylococcal osteoblast invasion. This adaptive mechanism, along with bioﬁlm formation, is associated with agr dysfunction, which can
be routinely assessed by delta-toxin detection using MALDI-TOF spectrum analysis, possibly providing clinicians with a diagnostic marker
of BJI chronicity at the time of diagnosis.
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p://dx.doi.org/10.1016/j.cmi.2015.01.026IntroductionStaphylococcus aureus is the leading cause of bone and joint in-
fections (BJI), described as difﬁcult-to-treat clinical entities due
to frequent bacterial persistence leading to chronicity and
relapse, despite 3–6-month antibiotic therapy associated with
complex surgical procedures [1,2]. The management strongly
differs between acute BJI, for which debridement with implantious Diseases. Published by Elsevier Ltd. All rights reserved
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the removal of any orthopaedic implants [3]. Patients with
chronic BJI are arbitrarily deﬁned, without any reliable biolog-
ical indicator, as patients with active BJI for over a month.
As BJI evolution delay can directly impact the medical and
surgical management of patients, an objective bacterial marker of
BJI chronicity is actually sorely lacking. Based on fundamental
studies, three staphylococcal phenotypic virulence factors are
thought to be potentially associated with BJI chronicity. First,
S. aureus is highly capable of forming bioﬁlm—a surface-attached
heterogeneous bacterial community encased with a self-
produced matrix composed of proteins, polysaccharides and
DNA. Due to its role as physical, chemical and enzymatic bar-
rier, bioﬁlm formation has been shown to be a mechanism for
evading host defences and resisting the effect of antimicrobials,
contributing to relapsing/chronic infections [4,5]. Then, if
S. aureus is primarily an extracellular pathogen, it has been re-
ported to invade and persist in non-professional phagocytic host
cells, including osteoblasts, leading to the constitution of a bac-
terial reservoir responsible for recurrence [6–8]. Finally, intra-
cellular lifestyle and growth within bioﬁlm are accompanied by
signiﬁcant changes in gene and protein expression, as well as
metabolic activity, leading to bacterial phenotype switching to
small-colony variants (SCVs), a particular population of persisting
bacteria which has been associated with BJI persistence [9–11].
In addition to these phenotypic virulence mechanisms, the dys-
regulation of accessory gene regulator (agr), a major regulon
controlling the expression of a plethora of S. aureus virulence
factors, has been associated with persistent infections [12–14].
In this context, we aimed to assess these different pheno-
typic and molecular bacterial markers for clinical relevance
toward early identiﬁcation of BJI chronicity at the time of
diagnosis.Materials and methodsEthical statements
This study received the approval of the French South-East
ethics committee (reference number 2013-018).
BJI deﬁnitions
All methicillin-susceptible S. aureus (MSSA) isolates responsible
for a ﬁrst episode of BJI in our institution from 2001 to 2011
were considered for inclusion. Patients with diabetic foot-
related or decubitus ulcer-related BJI were excluded because
of the particular pathophysiology and management of these
infections. Corresponding clinical data were retrospectively
collected from medical records on a standardized case record
form, and included demographic characteristics and patient co-Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infmorbidities (summarized in the modiﬁed Charlson co-
morbidity index), BJI clinical presentation, presence of biolog-
ical inﬂammatory syndrome (i.e. C-reactive protein plasma level
10 mg/L and/or white blood cell count 10 000/mm3), and
outcome. BJI were deﬁned as acute (infection lasting for 4
weeks) or chronic infections. Treatment failure included
persistent infection under appropriate antimicrobial therapy,
including the need for new surgery >5 days after the ﬁrst one,
and relapse after antimicrobial discontinuation.
Evaluation of staphylococcal interaction with human
osteoblasts
Staphylococcal interaction with osteoblasts was assessed in a
gentamicin protection assay, as previously described [15–17]. All
cell culture reagents were obtained from Gibco (Paisley, UK).
MG63 osteoblastic cell culture. The human osteoblastic cell line
MG63 (CRL-1427), purchased from LGC Standards (Tedding-
ton, UK), was cultured in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal calf serum, 25 mM HEPES, 2 mM
L-glutamine, 100 U/mL penicillin, and 100 mg/L streptomycin.
Before the assays, the osteoblasts were seeded at 40 000 cells
per well into 24-well tissue culture plates (Falcon, Le Pont de
Claix, France) in 1 mL of growth medium and were cultured for
2 days until 70–80% conﬂuence.
Bacterial suspension standardization and infection. Overnight
staphylococcal culture suspensions were diluted ﬁve-fold in fresh
brain–hearth infusion broth and further incubated in a gyratory
shaker for 3 h at 37°C to obtain mid-exponential-phase cultures.
These suspensions were washed, sonicated tominimize clumping,
and resuspended in antibiotic-free medium at a concentration
corresponding to an MOI of 100, using the following previously
established regression formula correlating bacterial density (CFU/
mL) with optical density at 600 nm (OD600): CFU/
mL = (7 × 108 × OD600) – (3 × 107) (data not shown). The
normalized bacterial suspensions were then added to osteoblast
cultures. After 2 h of co-culture, the infected osteoblasts were
incubated for 1 h with growth medium supplemented with
200 mg/L gentamicin (PAA, Pasching, Austria) to kill the remaining
extracellular staphylococcal cells. After 1 h, the cell culture me-
dium was replaced by growth medium supplemented with 40 μg/
mL gentamicin for 24 h to kill bacteria released upon host cell lysis,
so preventing these bacteria from infecting new host cells.
Evaluation of staphylococcal-induced cytotoxicity. After 24 h,
lactate dehydrogenase (LDH) release from damaged cells was
quantiﬁed in the cell culture supernatant using a colorimetric
method with a Dimension Vista automated clinical chemistry
analyser (Siemens Healthcare Diagnostics, Tarryton, NY). The
per cent mortality of osteoblasts was assessed by comparing
LDH release into the infected cell supernatant to that of un-
infected cells that were either left intact (lower control) or fullyectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e1–568.e11
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follows: ((LDH infected cells – LDH lower control)/(LDH
higher control – LDH lower control)) × 100. LDH release was
expressed relative to the 8325-4 reference strain.
Quantiﬁcation of internalized bacteria. After 24 h of gentamicin
treatment, aliquots of infected osteoblasts were lysed by a 10-
min incubation period in sterile water. Suspension dilutions of
these lysates were spiral-plated using a WASP automated plater
(AES Chemunex, Bruz, France). Colonies were enumerated
using an EasyCount automated plate reader (AES Chemunex).
Intracellular bacterial counts were expressed relative to the
8325-4 reference strain.
Evaluation of SCV phenotype switching. A commonly used
operational deﬁnition of SCVs based on colony size states that
colonies with a size less than one-ﬁfth of that of the wild-type
strain can be considered as SCVs [11]. Previous reports were
based on visual inspection of cultures by an operator. To
eliminate operator dependency, SCV quantiﬁcation was per-
formed using an automated process in which a high-resolution
picture of each plate was taken and analysed by means of the
image analysis software IMAGEJ (ImageJ, Rasband, W.S., National
Institutes of Health, Bethesda, MD, USA, 1997–2012) [18],
with a customized macro involving colour thresholding,
watershed algorithm and particle analysis, to extract the dis-
tribution of colony areas. Wild-type colony area was deﬁned as
the median area of all colonies (because median is robust to
outliers, the presence of SCVs did not inﬂuence this measure
signiﬁcantly) and SCVs were deﬁned, according to the usual
operational deﬁnition, as colonies with an area less than one-
ﬁfth of the median area.
Each isolate was evaluated in duplicate in a single experiment.
The S. aureus 8325-4 laboratory strain, which has been well
characterized with regard to its capacity to invade osteoblasts,
was used as a control in each experiment [15,16].
Bioﬁlm formation
The kinetics of bioﬁlm formation was explored using the BioFilm
Ring test (BioFilm Control, Saint Beauzire, France), as initially
described by Chavant et al. [19]. Brieﬂy, this technique is based
on the immobilization of magnetic microbeads when embedded
in bacterial bioﬁlms. After adjusting the OD600 of overnight
bacterial suspensions at 1 ± 0.05, the suspensions were diluted
1 : 250 in fresh brain–heart infusion medium, mixed with 1% of
magnetic microbeads suspension (“tonner”), and deposited in
triplicate in a 96-well microplate. Every 1 h for 5 h, the wells of
one plate were covered with 100 μL of contrast solution (white
opaque oil). The plate was then placed on a dedicated magnet
support for 1 min for contact magnetization and was then
scanned with a plate reader to obtain an image of the bottom of
each well. During contact magnetization, free beads are attractedClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectto the centre of the bottom of each well, forming a spot,
whereas the beads captured within a bioﬁlm remain in suspen-
sion. The BioFilm Control software (BIOFILM ELEMENTS) analyses
the images of each well before and after magnetization and cal-
culates the BioFilm Index (BFI). Each observed BFI (BFIo) was
normalized as a proportion of the immobilized beads (so-called
RBI for ‘Relative Bead Immobilization’) and was compared with
controls with (BFIreference) and without (BFIminimal) beads using
the following formula: RBI = ((BFIreference – BFIo) / (BFIreference –
BFIminimal)])
0.5 [19,20]. Forty isolates were tested, including all
agr-deﬁcient (i.e. delta-haemolysin-negative) isolates. Others
were randomly selected among the most prevalent clonal
complexes in a proportion representative of the repartition of
the entire collection.
Accessory gene regulator functionality
The multifunctional regulatory RNAIII, the main effector of the
agr system [21], is also a messenger RNA for the delta-toxin,
whose production is consequently a surrogate marker of agr
functionality [22]. Recently, it was shown that delta-toxin
production, and hence agr function, can be assessed using
whole cell matrix-assisted laser desorption ionization time-of-
ﬂight (MALDI-TOF) mass spectrometry (MS) during the
routine MS-mediated microbiological identiﬁcation process
[23]. Consequently, agr functionality was assessed by the eval-
uation of delta-toxin production from whole bacterial cells by
MALDI-TOF-MS spectrum analysis using an Axima Assurance®
mass spectrometer (Shimadzu Biotech, Noisiel, France) piloted
by LAUNCHPAD® software (version 2.8.4.20081127, Shimadzu
Biotech) with the conventional settings for bacterial identiﬁca-
tion [23,24]. Delta-toxin peak at 3005 ± 5 Thomson (or its
allelic variant at 3015 ± 5 Th) was searched manually in the MS
spectrum, as previously described [23].
Molecular characterization
DNA was extracted and puriﬁed using commercial extraction
kits (DNeasy kit and QIAcube instrument; Qiagen, Hilden,
Germany), according to the manufacturer’s protocol. The
DNA microarray Identibac S. aureus genotyping® (Alere
Technologies, Jena, Germany) used in this study and the related
procedures have been previously described in detail [25]. This
microarray allows the detection of 332 different target se-
quences corresponding to 185 genes and their allelic variants.
The isolate clonal complexes were determined by the com-
parison of the hybridization proﬁles to previously typed mul-
tilocus sequence typing reference strains [25].
Statistical analysis
Descriptive statistics were used to estimate the frequencies of
the study variables, expressed as the means and 95% conﬁdenceious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e1–568.e11
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used throughout to compare the study groups (the chi-squared
test with Yates’ correction, if needed, the Mann–Whitney U-test
for two-group difference analysis, and the Kruskal–Wallis test
for multiple pairwise comparisons) and to investigate correla-
tions (Spearman coefﬁcient), as appropriate. Phenotypic factors
(internalization, LDH release and SCV phenotype switching
rates), delta-toxin expression and virulence genes were included
in a binary logistic regression model to disclose risk factors for
chronicity, including variables with p-values <0.15 in the uni-
variate analysis in the ﬁnal model. For all tests, a p-value <0.05
was taken as signiﬁcant. All analyses were performed using SPSS
software version 17.0 (SPSS, Chicago, IL, USA).ResultsPopulation characteristics
A total of 211 patients with MSSA BJI were identiﬁed; six were
excluded because of the lack of available clinical data and three
due to chronic osteomyelitis resulting from diabetic perforating
ulcers. Among the 202 remaining patients, 86 isolates had not
been stored in the laboratory. Nineteen isolates collected at the
time of relapse and two stable SCVs were excluded. In total, 95
isolates responsible for 64 (67.4%) acute and 31 (32.6%)
chronic BJI were included (Table 1).
MSSA from chronic BJI shows a higher capacity to
invade human osteoblasts
The mean relative internalization rate within osteoblasts was
signiﬁcantly higher for chronic BJI isolates (240.7% of 8325-4TABLE 1. Characteristics of the 95 included patients with methicil
Total (n [ 95)
Demographic characteristics
Sex (male) 60 (63%)
Age (year) 53.6 (49.6–57.6)
Modiﬁed CCI 2.6 (2.1–3.2)
BJI type
Native septic arthritis 12 (13%)
Native osteomyelitis 12 (13%)
Vertebral osteomyelitis 7 (7%)
Orthopaedic device infection 64 (67%)
Osteosynthesis 32 (50%)
Prosthetic joint 29 (45%)
Others 3 (5%)
Biological inﬂammatory syndrome 88 (93%)
CRP level (mg/L) 170.5 (141.7–199.3)
WBC (/mm3) 10 790 (9985–11 600)
Neutrophil count (/mm3) 8129 (7338–8921)
Management
Surgical treatment 83 (87%)
Antimicrobial treatment duration (weeks) 27.8 (23.5–32.0)
Outcome
Treatment failure linked with the same strain 21 (22%)
Abbreviations: BJI, Bone and joint infection; CCI, Charlson comorbidity index; CRP, C-reac
Note: Results are presented as effective (%) and mean (95%CI) values. Comparisons betwee
Mann–Whitney U-test, as appropriate.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infinternalization rate; 95% CI, 171.3–310.2) than for acute BJI
isolates (162.7%; 95% CI, 132.3–193.0; p 0.035) (Fig. 1a).
Moreover, the internalization rate was correlated with the
infection evolution delay, i.e. the time from symptom onset to
microbiological diagnosis (Spearman coefﬁcient 0.29; p 0.005)
(Fig. 1b). No difference was observed between the two groups
regarding cytotoxicity at 24 h, with 10.7% (95% CI, 8.3–13.1)
and 7.6% (95% CI, 4.8–10.4) of cell death (p 0.152), respec-
tively (Fig. 1c). LDH release was not correlated with BJI evo-
lution delay (Spearman coefﬁcient –0.07; p 0.512). Similarly, no
difference in the capacities of the two groups to convert to the
SCV phenotype was observed, with SCV proportions of 3.3%
(95% CI, 2.8–3.7) and 3.4% (95% CI, 2.5–4.2) for the acute and
chronic MSSA BJI isolates, respectively (p 1.000) (Fig. 1d).
Bioﬁlm formation does not differ between acute and
chronic MSSA BJI isolates
The total immobilization of magnetic beads, reﬂecting bioﬁlm
formation, was observed within 5 h for all isolates. The kinetics
of bioﬁlm formation was similar for the acute and chronic BJI
isolates (Fig. 2). Of note, microarray data indicated that all
isolates harboured the bioﬁlm-associated genes icaA, icaC and
icaD (see below).
Genetic background analysis reveals a high diversity
among BJI MSSA clinical isolates, with no difference in
virulence gene distribution in acute and chronic BJI
isolates
Seventeen different clonal complexes were identiﬁed, of which
seven included more than ﬁve isolates (Table 2). No signiﬁcant
difference regarding the distribution of these clonal complexeslin-susceptible Staphylococcus aureus bone and joint infection
Acute BJI (n [ 64) Chronic BJI (n [ 31) p-value
38 (59%) 22 (71%) 0.272
56.1 (51.3–60.8) 48.5 (49.6–57.6) 0.105
2.9 (2.2–3.6) 2.0 (1.1–2.9) 0.148
10 (16%) 2 (7%) 0.351
2 (3%) 10 (32%) <0.001
5 (8%) 2 (7%) 0.856
47 (73%) 17 (55%) 0.070
23 (49%) 9 (53%) 0.777
22 (49%) 7 (41%) 0.689
2 (4%) 1 (6%) 0.691
59 (92%) 29 (94%) 0.811
209.8 (174.4-245.3) 86.23 (52.7–119.8) <0.0001
11 060 (10 140–11 970) 10 220 (8538–11 910) 0.098
8577 (7706–9448) 7169 (5492–8846) 0,009
57 (89%) 26 (84%) 0.700
26.4 (21.2–31.7) 30.6 (22.8–38.4) 0.244
14 (22%) 7 (23%) 0.938
tive protein; WBC, white blood cell.
n acute and chronic BJI were performed using a two-tailed Fisher’s exact test or a
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e1–568.e11
FIG. 1. Comparison of interactions between human osteoblasts and methicillin-susceptible Staphylococcus aureus (MSSA) isolates obtained from acute
and chronic bone and joint infections (BJI). (a) Internalization rate of MSSA isolates within human osteoblasts; (b) Correlation between the inter-
nalization rate of MSSA clinical isolates and BJI evolution delay; (c) Cytotoxicity rate induced by human osteoblast infection by MSSA isolates;
(d) proportion of phenotype switching to small-colony variants (SCVs).
568.e5 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIbetween acute and chronic BJI was observed (p 0.408). Using
multiple pairwise comparisons (Kruskal–Wallis test), no dif-
ferences were identiﬁed between the different clusters with
regard to their capacity to invade bone cells (p 0.446), cause cell
damage (p = 0.368), switch SCV phenotypes (p 0.054), or form
bioﬁlm (p 0.347) (Table 2, Fig. 3).
The distribution of virulence genes of the 95 BJI MSSA iso-
lates is presented in Table 3. No difference regarding theFIG. 2. Comparison of bioﬁlm formation by methicillin-susceptible
Staphylococcus aureus (MSSA) isolates obtained from acute and
chronic bone and joint infections (BJI).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectprevalence of these virulence factors between the acute and
chronic BJI MSSA isolates was noted. Logistic regression failed
to identify one of these virulence genes as a determinant for BJI
chronicity (Table 3).
agr dysfunction, detected through the absence of delta-
toxin production, is associated with MSSA BJI
chronicity, osteoblast invasion and bioﬁlm formation
Eighty isolates (84.2%) were considered to have a functional agr
system, as a delta-toxin peak (n = 76) or its allelic variant (n = 4)
was detected using MALDI-TOF-MS analysis. Interestingly,
delta-toxin negative strains tended to be more represented
among chronic (n = 8, 25.8%) than acute (n = 7, 10.9%) BJI
isolates (p 0.062), and the evolution delay of BJI was signiﬁcantly
higher in the delta-toxin negative isolates (17.4 weeks; 95% CI,
6.1–28.8) than in those with a functional agr system (6.4 weeks;
95% CI, 4.0–8.9; p 0.045). Compared with delta-toxin positive
isolates, the absence of delta-toxin expression was associated
with a higher internalization rate (337.1% of the 8325-4 inter-
nalization rate (95% CI, 219.5–454.7) versus 160.2% (95% CI,
133.9–186.5); p < 0.001), lower osteoblast cytotoxicity (64.5%
of 8325-4 LDH release (95% CI, 57.1–71.8) versus 87.3% (95%ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e1–568.e11
TABLE 2. Distribution of the major methicillin-susceptible Staphylococcus aureus clonal complexes regarding infection evolution
delay and comparison of their capacities to invade bone cells, induce cytotoxicity, and convert to a small-colony variant phenotype
CC Total
BJI chronicity
Internalization rate LDH release SCV proportion Delta-toxin negativeAcute BJI Chronic BJI
CC5 18 (19%) 13 (20%) 5 (16%) 215% (136–294) 77% (69–86) 3% (2–4) 6 (33%)
CC30 17 (18%) 10 (16%) 7 (23%) 170% (106–234) 85% (77–92) 5% (3–6) 1 (6%)
CC45 12 (13%) 10 (16%) 2 (7%) 280% (81–479) 97% (73–121) 3% (2–4) 1 (8%)
CC15 10 (11%) 8 (13%) 2 (7%) 186% (90–282) 94% (71–117) 2% (1–3) 3 (30%)
CC398 9 (10%) 6 (9%) 3 (10%) 103% (71–135) 72% (58–87) 3% (2–4) 1 (11%)
CC8 8 (8%) 3 (5%) 5 (16%) 248% (111–386) 79% (58–100) 5% (2–8) 0 (0%)
CC25 6 (6) 4 (6%) 2 (7%) 171% (–17 to 358) 89% (49–129) 3% (1–5) 1 (17%)
Others 10 different CC with less than 5 isolates each
Abbreviations: BJI, bone and joint infection; CC, Clonal complex; LDH, lactate dehydrogenase; SCV, small-colony variant.
Note: Results are presented as effective (%) and mean (95% CI) values and are expressed relative to the results obtained with the 8325-4 reference strain.
CMI Valour et al. Delta-toxin detection for MSSA BJI chronicity diagnosis 568.e6CI, 82.0–93.7), corresponding to 2.8% (95% CI, 0.6–5.0)
versus 11.0% (95% CI, 8.9-13.0) of cell death; p < 0.001), and an
accelerated bioﬁlm formation at each measurement point
(Fig. 4). No difference was detected regarding intracellular
phenotype switching to SCV (2.5%; 95% CI, 1.7–3.1) for the
delta-toxin-negative isolates versus 3.5% for the delta-toxin-
positive isolates (95% CI, 3.0–3.9; p 0.153). Of note, the
delta-toxin-negative isolates were not signiﬁcantly associatedFIG. 3. Comparison of the major methicillin-susceptible Staphylococcus aure
to invade bone cells, induce cytotoxicity, convert to a small-colony variant (SC
within human osteoblasts; (b) cytotoxicity rate induced by human osteoblas
SCVs; (d) bioﬁlm formation.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infwith one of the seven major staphylococcal clonal complexes (p
0.181).DiscussionStaphylococcal osteoblast invasion is considered as a patho-
physiological pathway of BJI on the basis of in vivo observationsus (MSSA) bone and joint infection (BJI) clones regarding their capacities
V) phenotype, and form bioﬁlm. (a) Internalization rate of MSSA isolates
t infection by MSSA isolates; (c) proportion of phenotype switching to
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e1–568.e11
TABLE 3. Distribution of virulence genes among acute and chronic bone and joint infection methicillin-susceptible Staphylococcus
aureus isolates and determinants of infection chronicity
Descriptive data Univariate analysis Multivariate analysis
Total Acute BJI Chronic BJI p value OR (95% CI) p value OR (95% CI) p value
Sex (male) 60 (63%) 38 (59%) 22 (71%) 0.503 1.436 (0.582–3.546) 0.432
Age (year) 53.6 (49.6–57.6) 56.1 (51.3–60.8) 48.5 (49.6–57.6) 0.105 0.984 (0.962–1.007) 0.175
Modiﬁed Charlson score 2.6 (2.1–3.2) 2.9 (2.2–3.6) 2.0 (1.1–2.9) 0.148 0.881 (0.737–1.053) 0.164
Internalization rate 1.000 (1.000–1.000) 0.101 1.000 (1.000–1.000) 0.244
LDH release 1.000 (1.000–1.000) 0.235
SCV 1.000 (1.000–1.000) 0.875
Delta-toxin negative 2.832 (0.920–8.715) 0.069 0.397 (0.708–8.112) 0.160
agr alleles 0.561 0.896 (0.525–1.532) 0.689
agr I 42 (44%) 26 (41%) 16 (52%) 1.559 (0.658–3.696) 0.313
agr II 29 (31%) 22 (34%) 7 (23%) 0.557 (0.207–1.495) 0.245
agr III 23 (24%) 15 (23%) 8 (26%) 1.136 (0.422–3.060) 0.801
agr IV 1 (1%) 1 (2%) 0 (0%) NC NC
Toxins
tst 16 (17%) 11 (17%) 5 (16%) 1.000 0.927 (0.291–2.946) 0.897
enterotoxins
Sea 17 (18%) 12 (19%) 5 (16%) 1.000 0.833 (0.265–2.618) 0.755
Seb 6 (6%) 4 (6%) 2 (7%) 1.000 1.034 (0.179–5.979) 0.970
Sec 7 (7%) 7 (11%) 0 (0%) 0.092 NC NC
Sed 8 (9%) 6 (9%) 2 (7%) 1.000 0.690 (0.131–3.641) 0.662
See 0 (0%) 0 (0%) 0 (0%) NC NC NC
Seg 58 (62%) 41 (65%) 17 (55%) 0.373 0.652 (0.271–1.566) 0.338
She 10 (11%) 7 (11%) 3 (10%) 1.000 0.872 (0.210–3.632) 0.851
Sei 59 (62%) 42 (66%) 17 (55%) 0.369 0.636 (0.265–1.527) 0.311
Sej 7 (7%) 5 (8%) 2 (7%) 1.000 0.814 (0.149–4.450) 0.812
Sek 5 (5%) 5 (8%) 0 (0%) 0.169 NC NC
seL 7 (7%) 7 (11%) 0 (0%) 0.092 NC NC
Sem 59 (62%) 42 (66%) 17 (55%) 0.369 0.636 (0.265–1.527) 0.311
Sen 58 (61%) 41 (64%) 17 (55%) 0.501 0.681 (0.285–1.630) 0.388
Seo 59 (62%) 42 (66%) 17 (55%) 0.369 0.636 (0.265–1.527) 0.311
Seq 5 (5%) 5 (8%) 0 (0%) 0.169 NC NC
Ser 7 (7%) 5 (8%) 2 (7%) 1.000 0.814 (0.146–4.450) 0.812
Seu 59 (62%) 42 (66%) 17 (55%) 0.369 0.636 (0.265–1.527) 0.311
lukS-PV– lukF-PV (PVL) 0 (0%) 0 (0%) 0 (0%) NC NC NC
lukD– lukE 52 (55%) 34 (53%) 18 (58%) 0.668 1.222 (0.514–2.904) 0.650
lukM– lukF-PV 0 (0%) 0 (0%) 0 (0%) NC NC NC
lukX 62 (90%) 41 (93%) 21 (84%) 0.245 0.384 (0.079–1.877) 0.237
lukY 65 (68%) 43 (67%) 22 (71%) 0.816 1.194 (0.469–3.040) 0.710
Exfoliative toxins
eta 0 (0%) 0 (0%) 0 (0%) NC NC NC
etb 0 (0%) 0 (0%) 0 (0%) NC NC NC
etd 6 (6%) 4 (6%) 2 (7%) 1.000 1.034 (0.179–5.979) 0.970
HLB conv phages
sak 72 (76%) 48 (75%) 24 (77%) 1.000 1.143 (0.414–3.152) 0.796
chp 68 (72%) 48 (75%) 20 (65%) 0.336 0.606 (0.240–1.533) 0.290
scn 90 (95%) 61 (95%) 29 (94%) 0.660 0.713 (0.113–4.504) 0.719
Proteases
splA 52 (55%) 34 (53.1%) 18 (58.1%) 0.668 1.222 (0.514–2.904) 0.650
splB 52 (55%) 34 (53.1%) 18 (58.1%) 0.668 1.222 (0.514–2.904) 0.650
splE 48 (51%) 30 (46.9%) 18 (58.1%) 0.383 1.569 (0.660–3.731) 0.308
Superantigens
setC 65 (68%) 43 (67%) 22 (71%) 0.816 1.194 (0.469–3.040) 0.710
set6 94 (99%) 64 (100%) 30 (97%) 0.326 NC NC
ssl1 95 (100%) 64 (100%) 31 (100%) NC NC NC
ssl2 95 (100%) 64 (100%) 31 (100%) NC NC NC
ssl3 69 (73%) 45 (70%) 24 (77%) 0.624 1.448 (0.534–3.928) 0.468
ssl4 82 (94%) 55 (95%) 27 (93%) 1.000 0.736 (0.116–4.672) 0.745
ssl5 95 (100%) 64 (100%) 31 (100%) NC NC NC
ssl6 23 (24%) 14 (22%) 9 (29%) 0.455 1.461 (0.551–3.877) 0.446
ssl7 94 (99%) 63 (98%) 31 (100%) 1.000 NC NC
ssl8 54 (57%) 36 (56%) 18 (58%) 1.000 1.077 (0.452–2.564) 0.867
ssl9 95 (100%) 64 (100%) 31 (100%) NC NC NC
ssl10 90 (100%) 61 (100%) 29 (100%) NC NC NC
ssl11 64 (70%) 43 (68%) 21 (72%) 0.809 1.221 (0.462–3.227) 0.687
Capsule and bioﬁlm-associated genes
cap1 0 (0%) 0 (0%) 0 (0%) NC NC NC
cap5 45 (47%) 28 (44%) 17 (55%) 0.382 1.561 (0.659–3.699) 0.312
cap8 50 (53%) 36 (56%) 14 (45%) 0.382 0.641 (0.270–1.518) 0.312
icaA 95 (100%) 64 (100%) 31 (100%) NC NC NC
icaC 95 (100%) 64 (100%) 31 (100%) NC NC NC
icaD 95 (100%) 64 (100%) 31 (100%) NC NC NC
bap 1 (1%) 0 (0%) 1 (3%) 0.326 NC NC
Adhesins (MSCRAMMs)
bbp 87 (92%) 59 (92%) 28 (90%) 0.713 0.791 (0.176–3.546) 0.791
clfA 95 (100%) 64 (100%) 31 (100%) NC NC NC
clfB 95 (100%) 64 (100%) 31 (100%) NC NC NC
cna 41 (43%) 30 (47%) 11 (36%) 0.378 0.623 (0.257–1.510) 0.295
ebh 93 (98%) 63 (98%) 30 (97%) 0.548 0.476 (0.029–7.876) 0.604
ebpS 95 (100%) 64 (100%) 31 (100%) NC NC NC
eno 95 (100%) 64 (100%) 31 (100%) NC NC NC
ﬁb 54 (57%) 36 (56%) 18 (58%) 1.000 1.077 (0.452–2.564) 0.867
fnbA 95 (100%) 64 (100%) 31 (100%) NC NC NC
fnbB 84 (88%) 56 (88%) 28 (90%) 1.000 1.333 (0.328–5.419) 0.688
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TABLE 3. Continued
Descriptive data Univariate analysis Multivariate analysis
Total Acute BJI Chronic BJI p value OR (95% CI) p value OR (95% CI) p value
map 92 (99%) 61 (95%) 31 (100%) 0.548 NC NC
sasG 45 (47%) 30 (47%) 15 (48%) 1.000 1.062 (0.450–2.507) 0.890
sdrC 94 (99%) 64 (100%) 30 (97%) 0.326 NC NC
sdrD 75 (79%) 54 (84%) 21 (68%) 0.105 0.389 (0.141–1.069) 0.067 0.365 (0.128–1.038) 0.059
vwb 95 (100%) 64 (100%) 31 (100%) NC NC NC
isaB 50 (56%) 33 (55%) 17 (59%) 0.822 1.159 (0.473–2.843) 0.747
hsdS1 0 (0%) 0 (0%) 0 (0%) NC NC NC
hsdS2 73 (77%) 50 (78%) 23 (74%) 0.796 0.805 (0.296–2.186) 0.670
hsdS3 60 (63%) 39 (61%) 21 (68%) 0.651 1.346 (0.545–3.328) 0.520
hysA1 94 (99%) 64 (100%) 30 (97%) 0.326 NC NC
hysA2 86 (91%) 56 (88%) 30 (97%) 0.263 4.286
(0.512–35.906)
0.180
Abbreviations: BJI, bone and joint infection; LDH, lactate dehydrogenase; NC: Not calculable; SCV, small-colony variant.
Note: Results are expressed as effective values (%). For each virulence factor, isolates with ambiguous detection were excluded from the denominator. For comparison between
acute and chronic BJI, p-values were calculated for each gene or allele using a two-tailed Fisher exact test. Association with chronicity was assessed using a binary logistic regression
analysis, including variables with p-values <0.15 in the ﬁnal regression model.
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though using only a few reference S. aureus isolates [6–8].
Intracellular persistence may constitute a strategy to escape the
action of the host immune system and antibiotics with exclusive
extracellular diffusion, constituting a bacterial reservoir that can
lead to chronicity or relapse [8]. This hypothesis has beenFIG. 4. Osteoblast invasion, cytotoxicity, and small-colony variant (SCV) i
(MSSA) bone and joint infection (BJI) isolates regarding the bacterial producti
osteoblasts; (b) cytotoxicity rate induced by human osteoblast infection with M
formation.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infpreviously investigated in our laboratory using the main circu-
lating methicillin-resistant S. aureus (MRSA) clones, showing
that community-acquired MRSA, usually responsible for acute
forms of BJI, were more cytotoxic and less internalized in os-
teoblasts than hospital-acquired MRSA, known to more
frequently induce indolent and recurrent BJI [16]. The presentntracellular emergence of methicillin-susceptible Staphylococcus aureus
on of delta-toxin. (a) Internalization rate of MSSA isolates within human
SSA isolates; (c) proportion of phenotype switching to SCVs; (d) bioﬁlm
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e1–568.e11
568.e9 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIresults conﬁrm the association between the staphylococcal
invasion of human osteoblasts and BJI chronicity for the ﬁrst
time among a large and highly diverse collection of clinical MSSA
isolates. Conversely, this important diversity in bacterial genetic
background may explain the difﬁculty in identifying any differ-
ence in cytotoxicity between chronic and acute BJI isolates, and
the less clear differences better than studies using a few well-
characterized laboratory reference isolates. Similarly, we
failed to disclose any association between chronicity and the
intracellular emergence of SCV. However, an accurate deﬁni-
tion of SCV, involving not only colony sizes but also metabolism
markers, for example, is lacking and may have helped to asso-
ciate this phenotype with chronic BJI forms. Indeed, SCVs have
been associated with S. aureus implanted-material infection and
BJI recurrence [9,10], and cell invasion has been described as a
putative mechanism of interconversion from the wild type to
the SCV phenotype [11].
The high genetic diversity of our isolate collection, the
absence of a direct relationship between BJI chronicity and
bacterial genetic backgrounds or virulence factors, and the as-
sociation of osteoblast invasion with agr deﬁciency all suggest
that an intra-osteoblastic lifestyle is an adaptive staphylococcal
mechanism leading to BJI chronicity rather than merely an
intrinsic feature. Indeed, the comparison of agr expression at
different time points during various infections has shown that
acute infections are usually associated with a functional agr
system [13]. The agr dysfunction appears to occur during the
course of infection and in cases of persistent bacteraemia,
diabetic foot infection or pulmonary infection in cystic ﬁbrosis
patients [12,13,23,26]. Additionally, chronicity of infection
appeared to be the major factor associated with agr dysfunction
in a previous series of 168 unselected clinical isolates [23].
In addition to the ﬁnding of a higher evolution delay of BJI in
agr-deﬁcient isolates, our results revealed a strong association
between agr dysfunction and the bacterial phenotypic mecha-
nisms associated with BJI chronicity, including: an enhanced
bioﬁlm formation, which had been previously suggested using
various laboratory strains and a few clinical isolates from
inhomogeneous pathological conditions [14,27,28]; and an
increased osteoblastic invasion, with reduced infection-induced
cytotoxicity. To our knowledge, the association of agr
dysfunction and non-professional phagocytic cell invasion has
only been described in airway epithelial cells [28]. Interestingly,
using isogenic mutants, we also linked the intraosteoblastic
cytotoxic phenotype of MRSA with the regulation of phenol-
soluble modulins (PSMs), which can be considered as major
effectors of intracellular staphylococcal virulence [16]. Indeed,
once internalized, S. aureus is initially trapped in phagosomes
[29]. PSM release may then results in phagosome membrane
disruption, leading to translocation of PSM in the cytosol, andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectultimately to host cell death [16]. Of note, PSM expression is
under direct control of agr and delta-toxin is known itself as
one of these PSM, called PSMγ. Put together, these consider-
ations may explain the reduced cell lysis observed in our study
in delta-toxin negative isolates, consequently promoting the
constitution of an intracellular staphylococcal reservoir leading
to chronicity.
Finally, it has been demonstrated that agr functionality can be
easily assessed by delta-toxin production using whole-cell
MALDI-TOF spectrum analysis [22,23]. As MALDI-TOF-MS is
increasingly being used in routine laboratory practice for bac-
terial identiﬁcation [23,30], it may provide in the same run
reliable information with respect to S. aureus agr functionality at
the time of BJI diagnosis, that is, when impaired, a predictive
marker of chronic infection [23]. It may provide pivotal infor-
mation for clinicians who currently lack objective criteria to
characterize the chronicity state of BJI in patients, and directly
impact their management. Notably, in the case of prosthetic
joint infection, the current guidelines arbitrarily tolerate implant
retention in cases of infection lasting for less than 3–4 weeks,
considering that surgical debridement associated with combi-
nation therapy including anti-bioﬁlm molecules, such as
rifampin, will avoid the development of chronicity and increase
the cure rate [3]. However, this decision is often very difﬁcult in
clinical practice, ﬁrst, because the delay of 3–4 weeks is only
theoretical, as bacterial adhesion and bioﬁlm formation are
highly likely to occur in the ﬁrst hours of infection; and second,
the clinical onset of infection is often difﬁcult to determine
because of the frequent occult evolution of BJI. In practice,
these factors contribute to a failure rate of implant retention
strategies that generally approaches 20% but can reach 50% in
some poorly explained cases [2,31,32]. Hence, prospective
evaluations of strategies using agr-deﬁciency detection at the
time of diagnosis to help in the management of BJI as acute or
chronic infections should be a priority according to their po-
tential clinical impact.ConclusionsUsing a large and non-clonal clinical collection of BJI MSSA iso-
lates, our ﬁndings suggest that bacterial invasion and intracellular
life switching within bone cells constitute a pivotal pathophysi-
ological mechanism of staphylococcal BJI chronicity, regardless
of the genetic background of the isolate. Moreover, the loss of
agr function that occurs during the infection course appears to be
linked with BJI chronicity through the promotion of an intra-
osteoblastic S. aureus reservoir by limiting intracellular staphy-
lococcal cell damage and through the enhancement of bioﬁlm
formation. As a consequence, the detection of delta-toxin byious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e1–568.e11
CMI Valour et al. Delta-toxin detection for MSSA BJI chronicity diagnosis 568.e10MALDI-TOF-MS, which is used in routine microbiology practice
for bacterial identiﬁcation, may provide a simple tool for the
detection of isolates associatedwith chronic forms of BJI andmay
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